A healthy biosimilar-led Q3 drives guidance upgrade
30/10/25 -"While Q3 sales fell marginally short of the street’s expectations, a healthily growing high-margin Biosimilars segment led to the 2025 profitability guidance upgrade. Going ahead, with a mix of ..."
Pages
54
Language
English
Published on
30/10/25
You may also be interested by these reports :
30/10/25
While Q3 sales fell marginally short of the street’s expectations, a healthily growing high-margin Biosimilars segment led to the 2025 profitability ...
29/10/25
The Q3 results exceeded expectations, driven by strong growth in the HIV, respiratory, immunology, oncology, and vaccines portfolio. Consequently, ...
28/10/25
The Q3 operating profitability was slightly behind the street’s expectations, though sales were in line with consensus. The quarterly performance was ...
24/10/25
The Q3 operating profitability came in considerably ahead of the street’s estimates, though sales met expectations. The performance was driven by ...